Abstract | AIM: The study investigated the direct effects of tramadol on the coagulation status of women with gynecologic malignancies in vitro. MATERIALS AND METHODS: Citrated whole-blood samples from 21 patients with gynecologic tumors were spiked ex vivo with 2 or 6 μl/ml tramadol. Thrombelastography (TEG) analysis was performed using ROTEM(®) to assess clotting time (CT), clot formation time (CFT) and maximum clot formation (MCF). RESULTS: In the INTEM assay, CT (P < 0.05) and CFT (P < 0.01) were significantly prolonged with tramadol at a 6 μl/ml concentration compared with baseline. There were no significant differences in MCF values between the baseline and the tramadol-treated samples (P > 0.05). Blood medicated with tramadol (6 μl/ml) clotted slowly (increased CT and CFT). CONCLUSION: The changes observed by TEG demonstrated that tramadol impairs hemostasis in a concentration-dependent manner in the whole blood of women with gynecologic malignancies in vitro.
|
Authors | Ayten Bilir, Meltem Olga Akay, Dilek Ceyhan, Neslihan Andıc |
Journal | Indian journal of pharmacology
(Indian J Pharmacol)
2014 Jul-Aug
Vol. 46
Issue 4
Pg. 413-5
ISSN: 1998-3751 [Electronic] India |
PMID | 25097280
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Analgesics, Opioid
- Tramadol
|
Topics |
- Analgesics, Opioid
(administration & dosage, adverse effects, therapeutic use)
- Blood Coagulation
(drug effects)
- Dose-Response Relationship, Drug
- Endometrial Neoplasms
(blood, drug therapy)
- Female
- Humans
- Thrombelastography
- Tramadol
(administration & dosage, adverse effects, therapeutic use)
- Uterine Cervical Neoplasms
(blood, drug therapy)
|